PreveCeutical Medical Inc (PRVCF)
OTHER OTC:PRVCF
Want to see PRVCF full AI Analyst Report?
PRVCF Stock Chart & Stats
$0.02
<$0.01(5.02%)
At close: 4:00 PM EST
$0.02
<$0.01(5.02%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.04
Previous CloseN/A
Volume198.43K
Average Volume (3M)90.41K
Market Cap
$8.62M
Enterprise Value$16.23M
Total Cash (Recent Filing)$103.68K
Total Debt (Recent Filing)$4.60M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding586,811,950
10 Day Avg. Volume24,507
30 Day Avg. Volume90,406
Financial Highlights & Ratios
PEG Ratio114.24
Price to Book (P/B)-2.02
Price to Sales (P/S)0.00
P/FCF Ratio-31.30
Enterprise Value/Market Cap1.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.60K
Enterprise Value/Ebitda-5.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused R&D In Pharmaceutical And Cannabinoid TherapeuticsThe company’s explicit focus on pharmaceutical and therapeutic technologies, including cannabinoid delivery platforms and drug-development programs, provides a clear strategic niche. A sustained R&D focus in a specialized therapeutic area can yield durable IP, regulatory pathways, and differentiated products if programs advance.
Corporate Restructuring And Financing ActionsCompletion of a spin-off and a private placement represents a structural corporate realignment and an infusion of capital. These actions can sharpen management focus on core programs and temporarily shore up liquidity, improving the company’s runway and execution capacity over the medium term.
Improving Free Cash Flow TrendWhile free cash flow remains negative in absolute terms, the positive growth metric vs. the prior period signals some improvement in cash conversion and expense control. If management sustains this trend, it supports longer-term cash stability and reduces immediate financing pressure.
Bears Say
No Revenue And Widening Operating LossesAbsence of operating revenue alongside widening losses is a fundamental weakness: it indicates lack of commercial validation and forces reliance on financing. Persisting negative earnings means continued cash drain and raises execution risk over the next several months absent product or partnership commercialization.
Stressed Balance Sheet: Negative Equity And High LeverageDeeply negative equity and debt that materially exceeds a thin asset base sharply reduce financial flexibility. This capital structure elevates default and dilution risk, constrains strategic options, and makes the company vulnerable to funding shortfalls over a multi-month horizon.
Ongoing Cash Burn And Reliance On External FundingSustained negative operating and free cash flow require frequent external financing. Reliance on placements and restructurings is a structural risk: future program advancement and shareholder dilution hinge on the company’s ability to raise capital, threatening continuity if markets tighten.
PreveCeutical Medical News
PRVCF FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was <$0.01 and its highest was $0.04 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is $8.62M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Jun 02, 2026 which is in 28 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
Currently, no data Available
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 586,811,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in PRVCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―
Ownership Overview
0.17%
Insiders
― Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---